title: Response to measles revaccination among Bolivian school-aged children.
abstract: The response to measles revaccination was evaluated in 1994 among 202 Bolivian school-aged children whose antibody levels were below 200 miu (milli-international units) by haemagglutination inhibition (HI) in a large-scale serosurvey conducted in Santa Cruz one year earlier. Of the 202 revaccinated children, 164 (82%) had seroconverted between the 1993 serosurvey and the pre-revaccination blood sample. A measles outbreak occurred in Santa Cruz 6 months before the revaccination. Among the seroconvertors, only 6% gave a history of measles, and 15% a history of contact with a case of measles. All 20 children with undetectable HI antibody pre-revaccination, and all 6 children with levels below 100 miu, seroconverted after revaccination. The geometric mean titres by HI at 4 weeks after revaccination were 2018 miu (95% confidence limits [95% CL] 1143, 3564) and 398 miu (95% CL 254, 625) in the 2 groups, respectively. Six of 9 children with pre-revaccination antibody titres of 100-199 miu also seroconverted. No child demonstrated a measles-specific immunoglobulin M response. Among the 29 children who seroconverted and were followed up at one year after revaccination, 15(52%) showed a fourfold or greater decline in antibody levels, which in 8 fell to levels below 200 miu. This study confirmed the observation that revaccination is successful in producing an antibody response in children with low or undetectable pre-revaccination titres, but it also confirmed that vaccine-induced immunity wanes rapidly.
authors.affiliation: Clinica Malattie Infettive, Università di Firenze, Italy. infdis@cesit1.unifi.it
authors.forename: A
authors.initials: A
authors.lastname: Bartoloni
authors.forename: F T
authors.initials: FT
authors.lastname: Cutts
authors.forename: P
authors.initials: P
authors.lastname: Guglielmetti
authors.forename: D
authors.initials: D
authors.lastname: Brown
authors.forename: M L
authors.initials: ML
authors.lastname: Bianchi Bandinelli
authors.forename: H
authors.initials: H
authors.lastname: Hurtado
authors.forename: M
authors.initials: M
authors.lastname: Roselli
mesh_terms: D000293:Adolescent; D000914:Antibodies, Viral / Q000097:blood*; D001838:Bolivia; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007117:Immunization, Secondary; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D008297:Male; D008457:Measles / Q000276:immunology / Q000517:prevention & control*; D008458:Measles Vaccine / Q000276:immunology*; D012737:Sex Factors; D013997:Time Factors
chemical_list: D000914:Antibodies, Viral; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D008458:Measles Vaccine